Can a new biologic drug delay dangerous lung Flare-Ups?

NCT ID NCT07720375

Not yet recruiting Disease control Sponsor: UCB Biopharma SRL Source: ClinicalTrials.gov ↗

First seen Jul 22, 2026 · Last updated Jul 24, 2026 · Updated 2 times

Summary

This phase 2 trial is testing whether an experimental biologic drug called galvokimig can delay the first moderate or severe lung infection (pulmonary exacerbation) in adults with non-cystic fibrosis bronchiectasis, a chronic lung condition that causes coughing, mucus buildup, and frequent infections. About 300 participants will receive either galvokimig or a placebo by injection for up to 52 weeks. The study aims to see if the drug reduces the need for antibiotics or hospital stays.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: an experimental biologic drug called galvokimig
What this could lead to: If successful, galvokimig could become a new treatment option to reduce serious lung infections in people with non-cystic fibrosis bronchiectasis.
What could go wrong: This is an early phase 2 trial, so the drug may not prove effective or safe. Side effects from a biologic injection are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-CYSTIC FIBROSIS BRONCHIECTASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bronchiectasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-CYSTIC FIBROSIS BRONCHIECTASIS

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.